Gabapentin Tablet, Film Coated
Product Images NDC 71205-457

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71205-457). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An illustration presenting the formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a factor adjustment for female patients.*

FDA Label Image

Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of Gabapentin, depicting its cyclohexane ring connected to aminoethyl and carboxymethyl functional groups.*

FDA Label Image

Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph showing mean pain score over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks with a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin shows a decreasing pain score trend compared to placebo.*

FDA Label Image

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph depicting mean pain scores over a 7-week period comparing placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The timeline includes a 3-week dose titration period followed by a 4-week fixed dose period. Pain scores decrease more with gabapentin doses than placebo over time.*

FDA Label Image

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) at different dosages across two studies. Study 1 shows 12% response for placebo and 29% for Gabapentin 3600 mg. Study 2 shows 14% for placebo, 32% for Gabapentin 1800 mg, and 34% for Gabapentin 2400 mg. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot chart showing percent difference on the vertical axis versus daily dose in milligrams on the horizontal axis. The chart compares three studies labeled Study a, Study b, and Study c, with data points for doses from 600 mg to 1800 mg.*

FDA Label Image

71205-457-90 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 06)

Gabapentin 600 mg tablets label by Proficient Rx LP, for human prescription drug. The label indicates 90 film-coated tablets, oval-shaped, scored and debossed with "NT" and "150". It includes storage instructions and manufacturer information, Strides Shasun Limited, India, with NDC 71205-457.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.